Company / Operating Cash Flow
Thermo Fisher Scientific Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$7.8B
FY2025
5-year range
$5.0B / $9.3B
FY2021-FY2025
Trend
-9.8%
vs FY2024
Sector context
#6 of 164
Health Care
What the data says
Among 164 Health Care companies, Thermo Fisher Scientific is in the top 4% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from $3.3B in FY2016 to $9.3B in FY2023.
Based on SEC 10-K filings.
$7.8B in FY2025 with a 5-year CAGR of -1.2%. Top quartile in the Health Care sector.
Declined from $9.3B to $7.8B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -1.9%
- 5-Year CAGR
- -1.2%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 164This company $7.8B Sector average $1.0B
▼
+649.0% above sector average
Key checks
Key Insights
- 5-year CAGR of -1.2%, indicating a declining trend.
- In FY2025, operating cash flow decreased 9.8% year-over-year.
- Ranks #6 out of 164 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.8B | -9.8% |
| FY2024 | $8.7B | -6.9% |
| FY2023 | $9.3B | +12.3% |
| FY2022 | $8.3B | +66.7% |
| FY2021 | $5.0B | -40.0% |
| FY2020 | $8.3B | +66.7% |
| FY2019 | $5.0B | +9.5% |
| FY2018 | $4.5B | +13.4% |
| FY2017 | $4.0B | +22.9% |
| FY2016 | $3.3B | +10.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026